Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

NOV 29, 2013 - Benzinga

A Must Read - Share

Goldman Sachs Comments on How Strong Sales of Kyprolis, Epogen, and Prolia Might Affect Amgen

In a report published Friday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating and $130.00 price target on Amgen (NASDAQ: AMGN). In the report, Goldman Sachs noted, “AMGN IMS monthly drug sales are tracking slight ahead of our estimates.

Tags: Goldman Sachs Comments on How Strong Sales of Kyprolis, Epogen, and Prolia Might Affect Amgen,  Amgen Latest News